Skip to main content
. 2016 Mar 23;7(17):24228–24241. doi: 10.18632/oncotarget.8286

Figure 3. Rapamycin enhances effects of cisplatin & radiation, sensitizing recurrent/metastatic cells to treatment.

Figure 3

(A) Representative images of colonies of mEERL and each MLM cell line formed with no treatment, CRT, rapamycin, or their combination in clonogenic assays. Representative images for MLM1 and MLM10 can be found enlarged to show detail in Supplementary Figure 2. (B) Average colony number (Top; *p < 0.044 to control, †p < 0.03 to control, ‡p < 0.02 to control, #p < 0.02 to individual treatments, **p < 0.02 to CRT only) and size (Bottom; *p < 0.006 to control, †p < 0.03 to control, ‡p < 0.003 to control, #p < 0.05 to individual treatments, **p < 0.05 to CRT only) from the triplicate wells represented in A as a fraction of control. (C) Average number (Top; *p < 0.047 to control, †p < 0.044 to control, ‡p < 0.008 to control, #p ≤ 0.05 to individual treatments) and size (Bottom; *p < 0.003 to control, †p < 0.03 to control, ‡p < 0.0009 to control, #p ≤ 0.05 to individual treatments) of colonies of mEERL and each MLM cell line formed in clonogenic assays as above but instead using cisplatin alone, without radiation. (D) Crystal violet assays using two HPV+ (SCC47 & SCC90) and two HPV- (SCC1 and SCC84) human HNSCC cell lines. Absorbance of crystal violet destain solution, a surrogate of total cell number, is shown as a fraction of control for each cell line under each of the indicated treatment conditions (*p < 0.006 to control, ‡p < 0.04 to individual treatments, †p < 0.04 to cisplatin only, #p < 0.02 to cisplatin/rapamycin). SD is shown by error bars.